{
  "ticker": "IBX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02976452",
  "id": "02976452",
  "pages": 6,
  "price_sensitive": false,
  "date": "20250804",
  "time": "0934",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250804/pdf/06mhk1f91vq65q.pdf",
  "summary": "### **Capital Raising Announcement Summary - IMAGION BIOSYSTEMS LIMITED (IBX)**  \n\n- **Structure**:  \n  - **Placement** (2 tranches):  \n    - **Tranche 1**: 45M ordinary shares (under ASX Listing Rules 7.1 & 7.1A).  \n    - **Tranche 2**: 188,333,333 ordinary shares (subject to shareholder approval).  \n  - **Attaching Securities**: 233,333,333 options (IBXO, expiry 13-Dec-2027) issued free with Placement shares.  \n  - **Lead Manager Options**: 26,250,000 unlisted options (exercise price $0.04, expiry 21-Sep-2028).  \n\n- **Key Terms**:  \n  - **Ordinary Shares (IBX)**:  \n    - Issue price: **AUD 0.015 per share**.  \n    - Total proceeds: **~AUD 3.5M** (Tranche 1: AUD 675k; Tranche 2: AUD 2.825M).  \n  - **Options (IBXO)**:  \n    - Free with Placement shares; implied value: **AUD 0.004 per option**.  \n\n- **Timetable**:  \n  - **Shareholder Meeting**: 18-Sep-2025 (approval for Tranche 2).  \n  - **Proposed Issue Date**: 22-Sep-2025.  \n\n- **Use of Funds**:  \n  - Advance **MagSense\u00ae technology** (HER2 Breast Cancer) and initiate Phase 1 trials for prostate/ovarian cancer.  \n\n- **Fees**:  \n  - Lead Manager (**CPS Capital**):  \n    - 2% management fee + 4% capital raising fee (payable in cash or Placement shares).  \n    - 26.25M unlisted options (exercise $0.04).  \n\n*Notes: No underwriting; no escrow/restrictions.*  \n\n*Brevity rule: Excluded boilerplate, non-material tranche details, and legal disclaimers.*",
  "usage": {
    "prompt_tokens": 2586,
    "completion_tokens": 448,
    "total_tokens": 3034,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-03T23:47:40.205862"
}